Current clinical data shows GLP-1 receptor agonists produce meaningful weight loss in many patients, yet 20-30% experience minimal response, suggesting personalization matters significantly
Further, as discussed in more detail in another section of this final rule with comment period, although the new requirements at 180.50 will be effective January 1, 2026, we are delaying enforcement of these requirements to April 1, 2026, to provide hospitals with more time to comply
it's the core of our operation
This suggests that young, female, lower-weight patients may be more susceptible to IGE from GLP-1RA therapy
Peptides are short chains of amino acids that serve as cellular messengers, regulating numerous processes such as: As the body ages, endogenous peptide levels decline, contributing to reduced healing, metabolic slowdown, and diminished resilience (Hobson et al., 2021)